Small molecule · developed by Ligand Pharmaceuticals
CE-Iohexol is a Captisol-Enabled formulation of iohexol, given as needed for a diagnostic procedure. It is studied in contrast-induced nephropathy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04627831 | Phase 2 | Contrast-induced Nephropathy | Withdrawn | LGND |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Contrast-induced Nephropathy
Updated Oct 18, 2026. Something wrong or missing? Report it on the LGND page.
See LGND's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LGND catalysts and pipeline →